Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 4 | 2018 | 206 | 1.850 |
Why?
|
| Dermatology | 6 | 2016 | 154 | 1.810 |
Why?
|
| Nevus, Pigmented | 3 | 2018 | 5 | 1.710 |
Why?
|
| Cosmetic Techniques | 3 | 2014 | 11 | 1.440 |
Why?
|
| Skin Diseases | 4 | 2016 | 138 | 1.380 |
Why?
|
| Psoriasis | 4 | 2018 | 334 | 1.120 |
Why?
|
| Melanoma | 2 | 2018 | 148 | 0.990 |
Why?
|
| Skin Aging | 2 | 2014 | 8 | 0.980 |
Why?
|
| Ambulatory Care | 3 | 2014 | 96 | 0.930 |
Why?
|
| Specialties, Surgical | 2 | 2013 | 24 | 0.930 |
Why?
|
| Dermatologic Agents | 2 | 2016 | 208 | 0.810 |
Why?
|
| Biological Therapy | 3 | 2018 | 20 | 0.750 |
Why?
|
| Humans | 31 | 2019 | 29123 | 0.740 |
Why?
|
| Skin | 2 | 2019 | 203 | 0.710 |
Why?
|
| Health Care Surveys | 4 | 2014 | 176 | 0.690 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2019 | 5 | 0.690 |
Why?
|
| Oxyphil Cells | 1 | 2018 | 2 | 0.680 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2018 | 3 | 0.680 |
Why?
|
| Metaplasia | 1 | 2018 | 20 | 0.680 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2017 | 2 | 0.640 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2018 | 12 | 0.640 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 23 | 0.630 |
Why?
|
| Neutrophils | 1 | 2018 | 102 | 0.610 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 114 | 0.610 |
Why?
|
| Surgery, Plastic | 2 | 2013 | 26 | 0.590 |
Why?
|
| Rosacea | 1 | 2017 | 46 | 0.580 |
Why?
|
| Skin Care | 1 | 2016 | 11 | 0.560 |
Why?
|
| Hair | 1 | 2016 | 28 | 0.560 |
Why?
|
| Scalp | 1 | 2016 | 33 | 0.550 |
Why?
|
| United States | 9 | 2018 | 3632 | 0.540 |
Why?
|
| Biological Factors | 1 | 2015 | 10 | 0.530 |
Why?
|
| Arthritis, Psoriatic | 1 | 2015 | 25 | 0.530 |
Why?
|
| Dermatitis, Atopic | 1 | 2017 | 86 | 0.530 |
Why?
|
| Female | 17 | 2019 | 18173 | 0.520 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 12 | 0.520 |
Why?
|
| Warts | 1 | 2014 | 2 | 0.510 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 68 | 0.510 |
Why?
|
| Aminoquinolines | 1 | 2014 | 16 | 0.510 |
Why?
|
| Antigens, CD | 1 | 2014 | 100 | 0.500 |
Why?
|
| Inflammation | 1 | 2018 | 507 | 0.490 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2014 | 2 | 0.490 |
Why?
|
| Adjuvants, Immunologic | 1 | 2014 | 51 | 0.490 |
Why?
|
| Medication Adherence | 1 | 2016 | 144 | 0.490 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 17 | 0.490 |
Why?
|
| Foreign-Body Reaction | 1 | 2013 | 5 | 0.480 |
Why?
|
| Mass Screening | 1 | 2015 | 223 | 0.460 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 210 | 0.450 |
Why?
|
| Dermoscopy | 1 | 2012 | 8 | 0.440 |
Why?
|
| Hospital Costs | 1 | 2012 | 36 | 0.430 |
Why?
|
| Health Care Costs | 1 | 2013 | 108 | 0.430 |
Why?
|
| Benchmarking | 1 | 2012 | 25 | 0.420 |
Why?
|
| Vitamin D | 1 | 2013 | 172 | 0.420 |
Why?
|
| Male | 13 | 2019 | 17815 | 0.400 |
Why?
|
| Burns | 1 | 2012 | 97 | 0.400 |
Why?
|
| African Americans | 2 | 2016 | 1373 | 0.390 |
Why?
|
| Exercise | 1 | 2016 | 592 | 0.390 |
Why?
|
| Administration, Cutaneous | 3 | 2016 | 107 | 0.370 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 142 | 0.370 |
Why?
|
| Faculty, Medical | 1 | 2010 | 69 | 0.360 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 493 | 0.360 |
Why?
|
| Orthopedics | 1 | 2010 | 93 | 0.350 |
Why?
|
| Adult | 8 | 2018 | 8426 | 0.350 |
Why?
|
| Continental Population Groups | 1 | 2010 | 221 | 0.340 |
Why?
|
| Students, Medical | 1 | 2010 | 121 | 0.340 |
Why?
|
| Biopsy | 3 | 2019 | 241 | 0.330 |
Why?
|
| Aged | 7 | 2019 | 9492 | 0.330 |
Why?
|
| Middle Aged | 7 | 2019 | 10834 | 0.310 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 519 | 0.300 |
Why?
|
| Internship and Residency | 1 | 2010 | 283 | 0.290 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 43 | 0.280 |
Why?
|
| Disease Management | 2 | 2019 | 114 | 0.280 |
Why?
|
| Polymethyl Methacrylate | 2 | 2014 | 11 | 0.250 |
Why?
|
| Lactic Acid | 2 | 2014 | 52 | 0.240 |
Why?
|
| Polymers | 2 | 2014 | 59 | 0.240 |
Why?
|
| Polyesters | 2 | 2014 | 72 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 77 | 0.210 |
Why?
|
| Young Adult | 2 | 2018 | 2402 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 285 | 0.180 |
Why?
|
| Glucocorticoids | 3 | 2019 | 149 | 0.180 |
Why?
|
| Sex Factors | 2 | 2013 | 631 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2019 | 7 | 0.180 |
Why?
|
| Cellulitis | 1 | 2019 | 11 | 0.180 |
Why?
|
| Pityriasis Lichenoides | 1 | 2019 | 3 | 0.180 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 20 | 0.180 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2019 | 4 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 10 | 0.170 |
Why?
|
| Plasmapheresis | 1 | 2019 | 9 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3101 | 0.170 |
Why?
|
| Drug Eruptions | 1 | 2018 | 8 | 0.170 |
Why?
|
| Quinolines | 1 | 2018 | 27 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 50 | 0.170 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 28 | 0.170 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2018 | 5 | 0.160 |
Why?
|
| Molluscum Contagiosum | 1 | 2018 | 3 | 0.160 |
Why?
|
| Interleukin-17 | 1 | 2018 | 14 | 0.160 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 41 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2018 | 16 | 0.160 |
Why?
|
| Ultraviolet Rays | 1 | 2017 | 46 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 167 | 0.150 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 436 | 0.150 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2016 | 8 | 0.150 |
Why?
|
| Family Practice | 2 | 2014 | 46 | 0.150 |
Why?
|
| Cytokines | 1 | 2018 | 243 | 0.140 |
Why?
|
| Meat | 1 | 2016 | 15 | 0.140 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 24 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2016 | 24 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 196 | 0.140 |
Why?
|
| Office Visits | 1 | 2016 | 71 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2016 | 113 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 246 | 0.130 |
Why?
|
| Adolescent | 2 | 2013 | 3255 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 3719 | 0.130 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 2 | 0.130 |
Why?
|
| Immunocompetence | 1 | 2014 | 12 | 0.130 |
Why?
|
| Durapatite | 1 | 2014 | 8 | 0.130 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 33 | 0.130 |
Why?
|
| Face | 1 | 2014 | 25 | 0.120 |
Why?
|
| Hyaluronic Acid | 1 | 2014 | 45 | 0.120 |
Why?
|
| General Surgery | 2 | 2014 | 81 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2019 | 1306 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 207 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 546 | 0.120 |
Why?
|
| Injections | 1 | 2013 | 61 | 0.120 |
Why?
|
| Botulinum Toxins | 1 | 2013 | 37 | 0.120 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 45 | 0.120 |
Why?
|
| Calcitriol | 1 | 2013 | 23 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2013 | 63 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 97 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 726 | 0.110 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 104 | 0.110 |
Why?
|
| Betamethasone | 1 | 2013 | 52 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 159 | 0.110 |
Why?
|
| Phenotype | 1 | 2014 | 629 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2012 | 16 | 0.110 |
Why?
|
| Australia | 1 | 2012 | 66 | 0.110 |
Why?
|
| Bandages | 1 | 2012 | 33 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 666 | 0.110 |
Why?
|
| Fluid Therapy | 1 | 2012 | 27 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 374 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 88 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 74 | 0.100 |
Why?
|
| Child | 2 | 2016 | 2219 | 0.100 |
Why?
|
| Length of Stay | 1 | 2012 | 292 | 0.100 |
Why?
|
| Medicine | 1 | 2010 | 30 | 0.100 |
Why?
|
| Asian Americans | 1 | 2010 | 98 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 1108 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2109 | 0.090 |
Why?
|
| Pemphigoid, Bullous | 2 | 2019 | 6 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1362 | 0.090 |
Why?
|
| Registries | 1 | 2010 | 278 | 0.090 |
Why?
|
| Animals | 2 | 2018 | 7299 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2016 | 3112 | 0.080 |
Why?
|
| Time Factors | 1 | 2013 | 2001 | 0.080 |
Why?
|
| Quality of Life | 1 | 2013 | 816 | 0.080 |
Why?
|
| European Continental Ancestry Group | 1 | 2010 | 1131 | 0.070 |
Why?
|
| Hispanic Americans | 1 | 2010 | 904 | 0.060 |
Why?
|
| Streptococcus | 1 | 2019 | 7 | 0.050 |
Why?
|
| Thigh | 1 | 2019 | 39 | 0.040 |
Why?
|
| Dermatitis Herpetiformis | 1 | 2019 | 1 | 0.040 |
Why?
|
| Epidermolysis Bullosa Acquisita | 1 | 2019 | 1 | 0.040 |
Why?
|
| Pemphigoid Gestationis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 89 | 0.040 |
Why?
|
| Fever | 1 | 2019 | 56 | 0.040 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2019 | 3 | 0.040 |
Why?
|
| Pemphigus | 1 | 2019 | 8 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 21 | 0.040 |
Why?
|
| Acneiform Eruptions | 1 | 2018 | 1 | 0.040 |
Why?
|
| Methotrexate | 1 | 2019 | 60 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 36 | 0.040 |
Why?
|
| Phototherapy | 1 | 2019 | 47 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 273 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2019 | 48 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 45 | 0.040 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2018 | 2 | 0.040 |
Why?
|
| Biofilms | 1 | 2018 | 24 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2018 | 10 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2016 | 78 | 0.040 |
Why?
|
| Encephalopathy, Bovine Spongiform | 1 | 2016 | 2 | 0.040 |
Why?
|
| Cattle | 1 | 2016 | 100 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 863 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 430 | 0.030 |
Why?
|
| Pregnancy | 1 | 2019 | 815 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 66 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 417 | 0.030 |
Why?
|
| Infant | 1 | 2016 | 969 | 0.030 |
Why?
|
| Pediatrics | 1 | 2014 | 132 | 0.030 |
Why?
|
| North Carolina | 1 | 2016 | 1423 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2014 | 307 | 0.030 |
Why?
|